Overview

Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

Status:
Recruiting
Trial end date:
2023-12-08
Target enrollment:
Participant gender:
Summary
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic tachycardia syndrome (POTS) (post-COVID-19 POTS).
Phase:
Phase 2
Details
Lead Sponsor:
argenx
Collaborator:
Iqvia Pty Ltd